Glutathione for Mold Detox

Creator: Superpower
Published: 2026-03-24

Understand what your organ health supplements results really mean

See your biomarkers in context with a comprehensive panel.

CLIA-certified labs
HIPAA compliant
Personalized health protocol

What glutathione does and why mold toxins target it

Glutathione is a tripeptide made from three amino acids: cysteine, glutamate, and glycine. It's synthesized in every cell in the body, but its highest concentrations are in the liver, where it serves as the primary molecule for phase II detoxification. Glutathione doesn't just neutralize free radicals; it binds directly to toxins, drugs, and metabolic waste products through a process called conjugation, rendering them water-soluble so they can be excreted in bile or urine.

Mycotoxins (the toxic secondary metabolites produced by molds like Aspergillus, Penicillium, and Stachybotrys) are lipophilic. They accumulate in fat tissue, cell membranes, and the brain. The body's primary strategy for clearing them is glutathione conjugation, facilitated by a family of enzymes called glutathione S-transferases (GSTs). When GSTs attach glutathione to a mycotoxin molecule, the resulting conjugate is recognized as waste and shuttled out of the body.

Mycotoxins don't just consume glutathione; they actively suppress its production. Research published in Toxins demonstrates that mycotoxins like ochratoxin A and aflatoxin downregulate the expression of genes encoding the enzymes needed to synthesize glutathione, including glutamate-cysteine ligase and glutathione synthetase. This creates a double hit:

The toxins use up existing glutathione stores while simultaneously blocking the cell's ability to make more.
The result is oxidative stress, mitochondrial dysfunction, and impaired detoxification capacity, all hallmarks of chronic inflammatory response syndrome (CIRS).

The evidence for glutathione depletion in mold illness

The link between mycotoxin exposure and glutathione depletion is well-documented in both animal and human studies. Animal research has found that exposure to citrinin (a mycotoxin produced by Penicillium and Aspergillus species) lowers glutathione levels in the kidney while driving up markers of oxidative damage. Similar findings have been reported for aflatoxin B1, which depletes hepatic glutathione and increases lipid peroxidation, a marker of oxidative damage.

In humans, individuals with CIRS often present with elevated markers of oxidative stress, including malondialdehyde and 8-hydroxy-2'-deoxyguanosine, alongside low antioxidant capacity. While direct measurement of intracellular glutathione is not part of routine clinical testing, these surrogate markers suggest that glutathione reserves are compromised. Functional medicine practitioners often use red blood cell glutathione or oxidized-to-reduced glutathione ratios as more sensitive indicators of status, though these tests are not widely available in conventional labs.

The clinical significance of glutathione depletion extends beyond detoxification:

Glutathione is required for proper immune function, particularly for T-cell proliferation and natural killer cell activity.
It protects mitochondria from oxidative damage, which is critical because mitochondrial dysfunction is a central feature of CIRS.
When glutathione is depleted, the immune system becomes dysregulated, energy production falters, and the inflammatory cascade perpetuates itself.

How glutathione clears mycotoxins from the body

Glutathione's role in mycotoxin detoxification is mechanistically specific. Once a mycotoxin enters the bloodstream, it is taken up by hepatocytes, where it undergoes phase I metabolism via cytochrome P450 enzymes. This step often makes the toxin more reactive, not less. Phase II conjugation with glutathione, catalyzed by GSTs, neutralizes this reactivity and adds a polar group that allows the conjugate to be excreted.

Different mycotoxins are processed by different GST isoforms. For example, aflatoxin B1 is conjugated primarily by GSTA1 and GSTM1, while ochratoxin A relies more heavily on GSTP1. Genetic polymorphisms in these enzymes, which are common, can significantly affect an individual's ability to detoxify mold toxins. People with null variants of GSTM1 or GSTT1, for instance, have reduced capacity to conjugate certain mycotoxins and may be more susceptible to chronic mold illness.

Once conjugated, the glutathione-mycotoxin complex is transported into bile via ATP-binding cassette (ABC) transporters, particularly multidrug resistance-associated protein 2 (MRP2). From bile, the conjugate enters the intestine, where it should be excreted in stool. However, if gut bacteria produce beta-glucuronidase (an enzyme that cleaves conjugates), the mycotoxin can be reabsorbed in a process called enterohepatic recirculation. This is one reason why addressing gut health and bile flow is essential in mold detoxification protocols.

A smaller fraction of glutathione-mycotoxin conjugates is excreted via the kidneys. This pathway is particularly relevant for water-soluble mycotoxins or those that have undergone additional phase II modifications, such as sulfation or acetylation. Urinary mycotoxin testing, which measures metabolites rather than parent compounds, reflects the body's detoxification activity rather than total body burden.

Dose, form, and timing: What the evidence supports

Form

Oral glutathione has historically been dismissed as ineffective because it is broken down by peptidases in the gut. However, liposomal formulations (which encapsulate glutathione in phospholipid vesicles) protect it from enzymatic degradation and enhance absorption. A 2015 study in the European Journal of Nutrition demonstrated that standard oral glutathione significantly increased body stores of glutathione in healthy adults over six months of daily supplementation. Sublingual glutathione, which bypasses first-pass metabolism, is another option, though data on its efficacy are more limited.

Intravenous (IV) glutathione delivers the molecule directly into the bloodstream, bypassing the gut entirely. This is the most effective route for rapid repletion, particularly in individuals with severe depletion or impaired gut absorption. IV doses typically range from 1,000 to 2,000 mg per session, administered one to three times per week. The effects are immediate but transient; glutathione has a short half-life in the blood, and tissue uptake depends on the presence of transporters and adequate cofactors.

N-acetylcysteine (NAC), a precursor to glutathione, is often used as an alternative or adjunct. NAC provides cysteine (the rate-limiting amino acid in glutathione synthesis) and has been shown to increase intracellular glutathione in multiple studies (2022 rct). NAC doses used for glutathione support vary based on individual need and the clinical context. NAC is particularly useful for individuals who cannot access IV therapy or who need long-term support. However, it requires functional enzyme pathways to convert cysteine into glutathione, which may be impaired in CIRS.

Dose

For oral liposomal glutathione, clinical research has explored a range of daily doses:

Lower doses (250 to 500 mg) are appropriate for maintenance or mild depletion.
Higher doses (750 to 1,000 mg) are used in active detoxification protocols.
There is no established upper tolerable limit for glutathione, and adverse effects are rare, though some individuals report mild gastrointestinal upset at higher doses.

For NAC as a glutathione precursor, divided daily dosing is commonly used in clinical practice. Higher doses (up to 1,800 mg) may be used in acute settings, such as acetaminophen overdose, but are not typically necessary for chronic mold detoxification.

Timing

Glutathione is best taken on an empty stomach to maximize absorption, though liposomal forms are less sensitive to food interference. NAC can be taken with or without food. Timing relative to other supplements matters: glutathione and NAC should not be taken simultaneously with high doses of vitamin C, as ascorbic acid can reduce disulfide bonds and convert oxidized glutathione back to its reduced form prematurely, potentially interfering with its function as a redox buffer.

Cofactors

Glutathione synthesis and recycling require several cofactors:

Selenium is essential for glutathione peroxidase, the enzyme that uses glutathione to neutralize hydrogen peroxide.
Riboflavin (vitamin B2) is required for glutathione reductase, which regenerates reduced glutathione from its oxidized form.
Magnesium supports the ATP-dependent steps of glutathione synthesis.
Deficiencies in any of these nutrients will limit the effectiveness of glutathione supplementation.

Superpower's nutrition panel includes selenium, magnesium, and markers that reflect B vitamin status, offering insight into whether these cofactor pathways are intact.

Test 150+ biomarkers

Two blood draws. A full picture of your health, explained in plain language.

Book your test

Test 150+ biomarkers

Two blood draws. A full picture of your health, explained in plain language.

Book your test

Who benefits most and who should exercise caution

Individuals with confirmed or suspected CIRS, particularly those with documented mycotoxin exposure, are the primary candidates for glutathione repletion. This includes people who have lived or worked in water-damaged buildings, those with positive urinary mycotoxin tests, and those with symptom clusters consistent with mold illness: chronic fatigue, cognitive dysfunction, joint pain, respiratory symptoms, and dysautonomia.

Genetic factors influence response. Individuals with polymorphisms in GST genes (particularly GSTM1-null and GSTT1-null genotypes) have reduced capacity to conjugate toxins and may benefit more from direct glutathione supplementation than from precursor strategies like NAC. MTHFR variants, which impair methylation, can also affect glutathione metabolism, as methylation is required to regenerate methionine from homocysteine, a pathway that indirectly supports glutathione synthesis.

Gut health is a critical variable. Individuals with leaky gut, dysbiosis, or impaired bile flow may not absorb oral glutathione effectively, even in liposomal form. In these cases, IV therapy or addressing gut integrity first may be necessary. Binders like cholestyramine or activated charcoal, commonly used in mold protocols, can interfere with glutathione absorption if taken too close together; spacing by at least two hours is recommended.

Caution is warranted in individuals with active cancer, as glutathione can protect cancer cells from oxidative stress and potentially reduce the efficacy of certain chemotherapies. This is a nuanced issue; glutathione depletion is also associated with cancer progression, and the timing and context of supplementation matter. Consultation with an oncologist is essential.

People with sulfur sensitivity or CBS (cystathionine beta-synthase) upregulation may not tolerate NAC or high-sulfur foods, as these can exacerbate symptoms like brain fog, irritability, and histamine intolerance. In these cases, liposomal glutathione or glycine-based support may be better tolerated.

Testing glutathione status and tracking recovery

Direct measurement of intracellular glutathione is not part of standard lab panels. Serum glutathione reflects extracellular levels, which do not correlate well with tissue stores. Red blood cell (RBC) glutathione is a more accurate marker of intracellular status, though it is not widely available. The oxidized-to-reduced glutathione ratio (GSSG:GSH) is an even more sensitive indicator of oxidative stress and redox imbalance, but it requires specialized testing.

In the absence of direct glutathione measurement, clinicians rely on surrogate markers:

Elevated high-sensitivity C-reactive protein (hs-CRP), malondialdehyde, and 8-OHdG suggest oxidative stress and, by inference, glutathione depletion.
Low levels of selenium, magnesium, or B vitamins indicate that cofactor pathways may be compromised.
Elevated liver enzymes, particularly gamma-glutamyl transferase (GGT), can reflect increased demand for glutathione conjugation, though GGT is also elevated in alcohol use and other liver conditions.

Functional markers of detoxification capacity include urinary mycotoxin levels, which should decrease over time as glutathione-dependent conjugation improves. Symptom resolution, particularly improvements in fatigue, cognitive function, and inflammatory markers, is the most clinically relevant endpoint. Tracking hs-CRP, liver enzymes, and nutrient cofactors over time provides objective data on whether the intervention is working.

Building the right foundation before you add another supplement

Glutathione supplementation is not a standalone solution. If you're still living or working in a moldy environment, no amount of glutathione will outpace the rate at which toxins are depleting it. Remediation comes first. Binders like cholestyramine, activated charcoal, or bentonite clay are often used in parallel to sequester mycotoxins in the gut and prevent reabsorption. Supporting bile flow with nutrients like taurine, phosphatidylcholine, or milk thistle ensures that conjugated toxins are efficiently excreted.

Superpower's 150+ biomarker panel includes the markers that tell you whether your body has the resources to detoxify effectively: selenium, magnesium, liver enzymes, inflammatory markers, and the broader metabolic context that determines how well you absorb and use what you're taking. Glutathione mold detox isn't about guessing; it's about measuring, intervening, and tracking whether the intervention is moving the needle. Most people supplementing glutathione are doing so without knowing their baseline oxidative stress, cofactor status, or whether their liver is even capable of processing what they're giving it. Testing first transforms supplementation from a shot in the dark into a targeted protocol.

Frequently Asked Questions

Mycotoxins such as ochratoxin A and aflatoxin actively suppress glutathione production by downregulating the genes that encode glutamate-cysteine ligase and glutathione synthetase — the two enzymes responsible for building the glutathione molecule. At the same time, each mycotoxin being detoxified consumes a molecule of glutathione through conjugation. The result is simultaneous depletion of existing stores and suppression of new synthesis, a double hit that drives the oxidative stress and mitochondrial dysfunction characteristic of CIRS.

Citrinin, produced by Penicillium and Aspergillus species, causes dose- and time-dependent decreases in intracellular glutathione in kidney cells, as documented in a 2014 Journal of Applied Toxicology review. Aflatoxin B1, a hepatotoxin from Aspergillus, depletes hepatic glutathione and accelerates lipid peroxidation. Ochratoxin A downregulates glutathione synthesis genes and relies on the GSTP1 enzyme for its own conjugation, making it particularly damaging when GST activity is already reduced.

After the liver conjugates a mycotoxin with glutathione, the resulting complex is transported into bile and should exit the body in stool. However, certain gut bacteria produce beta-glucuronidase, an enzyme that cleaves the glutathione conjugate and releases the free mycotoxin back into the intestine, where it is reabsorbed into the bloodstream. This cycle of excretion and reabsorption, called enterohepatic recirculation, continually returns mycotoxins to the liver for reprocessing, sustaining the drain on glutathione reserves and prolonging exposure even after leaving a moldy environment.

Different mycotoxins are processed by specific GST isoforms. Aflatoxin B1, for example, relies primarily on GSTA1 and GSTM1 for conjugation, while ochratoxin A depends more heavily on GSTP1. People who carry null variants of GSTM1 or GSTT1 — which are common in the general population — have functionally absent copies of those enzymes, meaning certain mycotoxins cannot be efficiently conjugated and accumulate instead. These individuals may be more susceptible to developing chronic mold illness and are likely to benefit more from direct glutathione supplementation than from precursor-only strategies.

NAC supplies cysteine, the rate-limiting amino acid in glutathione synthesis, and relies on the body's own enzyme pathways to convert it into glutathione. This makes NAC less effective in CIRS, where those enzymatic pathways may be impaired by the mycotoxin-induced suppression of glutathione synthetase. Liposomal glutathione delivers the intact molecule encapsulated in phospholipid vesicles that protect it from gut breakdown, making it better suited for individuals with compromised synthesis capacity. A 2015 European Journal of Nutrition study confirmed that liposomal glutathione significantly increased blood levels in healthy adults over six months.

Three cofactors are essential for glutathione to be synthesized and recycled effectively. Selenium is required for glutathione peroxidase, which uses glutathione to neutralize hydrogen peroxide. Riboflavin (vitamin B2) powers glutathione reductase, the enzyme that converts oxidized glutathione back into its active reduced form. Magnesium supports the ATP-dependent steps of glutathione synthesis. Deficiency in any one of these will limit how much functional glutathione the body can produce or maintain, regardless of how much supplemental glutathione is taken.

Mycotoxins are lipophilic and accumulate continuously in fat tissue, cell membranes, and the brain with each new exposure. Glutathione conjugation can only clear what has already entered the liver — it cannot outpace ongoing absorption from a contaminated environment. If supplementation begins while exposure continues, the toxin load entering the body will simply exceed the clearance capacity that glutathione supports, and depletion will persist. Remediation — removing or leaving the moldy environment — must come first so that the body's detoxification machinery is not overwhelmed before it can begin to recover.

Because intracellular glutathione is not routinely measured in standard labs, surrogate markers are used. Elevated hs-CRP, malondialdehyde, and 8-OHdG indicate oxidative stress consistent with glutathione depletion. Gamma-glutamyl transferase (GGT) rises when the liver is under elevated conjugation demand. Low serum selenium, magnesium, or B vitamin markers reveal that the cofactor pathways supporting glutathione synthesis may be compromised. Tracking these markers over time alongside urinary mycotoxin levels provides objective evidence of whether glutathione-dependent detoxification is improving.